Literature DB >> 30445605

Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable.

Francesco Cosentino1, Antonio Ceriello2,3, Florian M M Baeres4, Paola Fioretto5, Alan Garber6, Wendy Gattis Stough7, Jyothis T George8, Peter J Grant9, Kamlesh Khunti10, Anna Maria Langkilde11, Jorge Plutzky12, Lars Rydén13, André Scheen14, Eberhard Standl15, Jaakko Tuomilehto16,17,18, Faiez Zannad19,20,21.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30445605     DOI： 10.1093/eurheartj/ehy677

Source DB:  PubMed          Journal:  Eur Heart J        ISSN： 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  9 in total

1.  Prescribing diabetes medication for cardiovascular risk reduction in patients admitted with acute coronary syndromes: a survey of cardiologists' attitudes and practice.

Authors:  Thomas A Slater; Michael Drozd; Victoria Palin; Charlotte Bowles; Mohammed A Waduud; Rani Khatib; Ramzi A Ajjan; Stephen B Wheatcroft
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2020-07-01

2.  Cardiovascular and renal protection with sodium-glucose cotransporter type 2 inhibitors: new paradigm in type 2 diabetes management…and potentially beyond.

Authors:  André J Scheen
Journal:  Ann Transl Med       Date:  2019-07

Review 3.  Diabetes Mellitus and Cardiovascular Disease.

Authors:  Ann Marie Schmidt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-04       Impact factor: 8.311

4.  Antithrombotic therapy in diabetes: which, when, and for how long?

Authors:  Ramzi A Ajjan; Noppadol Kietsiriroje; Lina Badimon; Gemma Vilahur; Diana A Gorog; Dominick J Angiolillo; David A Russell; Bianca Rocca; Robert F Storey
Journal:  Eur Heart J       Date:  2021-06-14       Impact factor: 29.983

5.  A healthy lifestyle mitigates the risk of heart disease related to type 2 diabetes: a prospective nested case-control study in a nationwide Swedish twin cohort.

Authors:  Rongrong Yang; Hui Xu; Nancy L Pedersen; Xuerui Li; Jing Yu; Cuiping Bao; Xiuying Qi; Weili Xu
Journal:  Diabetologia       Date:  2020-11-10       Impact factor: 10.122

6.  Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.

Authors:  Desye Gebrie; Desalegn Getnet; Tsegahun Manyazewal
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

7.  HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target.

Authors:  Antonio Ceriello; Giuseppe Lucisano; Francesco Prattichizzo; Rosalba La Grotta; Stefan Franzén; Ann-Marie Svensson; Björn Eliasson; Antonio Nicolucci
Journal:  Cardiovasc Diabetol       Date:  2022-01-24       Impact factor: 9.951

8.  Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient!

Authors:  Niki Katsiki; Maciej Banach; Dimitri P Mikhailidis
Journal:  Arch Med Sci       Date:  2019-11-03       Impact factor: 3.318

9.  Metformin-Insulin versus Metformin-Sulfonylurea Combination Therapies in Type 2 Diabetes: A Comparative Study of Glycemic Control and Risk of Cardiovascular Diseases in Addis Ababa, Ethiopia.

Authors:  Desye Gebrie; Tsegahun Manyazewal; Dawit A Ejigu; Eyasu Makonnen
Journal:  Diabetes Metab Syndr Obes       Date:  2021-07-24       Impact factor: 3.168
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.